ToolGen Files Patent Infringement Lawsuit Against Vertex in the United Kingdom

CASGEVY became the world's first genome editing therapy to receive marketing authorization, beginning with the United Kingdom in November 2023, followed by the European Commission (EC) in February 2024. It provides a novel treatment for patients with sickle cell disease and beta-thalassemia. The one-time treatment is reportedly priced at approximately £1.7 million (approx. $2.2 million USD), with sales projections indicating blockbuster potential. In December 2023, Vertex entered into a licensing agreement with Editas Medicine for CRISPR genome editing technology.

ToolGen's CEO Jong Sang Ryu commented, "Vertex's CASGEVY was born from ToolGen's proprietary CRISPR RNP technology. As the company behind the world's first CRISPR Cas9-based gene therapy, we believe Vertex should fairly recognize ToolGen's contribution through appropriate licensing for the use of our CRISPR Cas9 and CRISPR RNP technologies in developing this innovative treatment."

He continued, "This lawsuit is not aimed at restricting patient access to CASGEVY in the United Kingdom. Rather, it seeks to ensure ToolGen is properly acknowledged and rewarded through a fair licensing agreement."

View original content:https://www.prnewswire.co.uk/news-releases/toolgen-files-patent-infringement-lawsuit-against-vertex-in-the-united-kingdom-302433170.html